Novel 3-azaindolyl-4-arylmaleimides exhibiting potent antiangiogenic efficacy, protein kinase inhibition, and antiproliferative activity

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9531-9540

  Ganser, Christopher ^a   Lauermann, Eva ^a   Maderer, Annett ^a   Stauder, Torsten ^a   Kramb, Jan Peter ^a   Plutizki, Stanislav ^a   Kindler, Thomas ^a   Moehler, Markus ^a   Dannhardt, Gerd ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 ( 2 AZAINDOL 3 YL) 4 ( 3,4,5 TRIMETHOXYPHENYL)MALEIMIDE; 3 ( 4 AZAINDOL 3 YL) 4 ( 3,4,5 TRIMETHOXYPHENYL)MALEIMIDE; 3 ( 5 AZAINDOL 3 YL) 4 ( 3,4,5 TRIMETHOXYPHENYL)MALEIMIDE; 3 ( 6 AZAINDOL 3 YL) 4 ( 3,4,5 TRIMETHOXYPHENYL)MALEIMIDE; 3 ( 7 AZAINDOL 3 YL) 4 ( 2 METHOXYPHENYL)MALEIMIDE; 3 ( 7 AZAINDOL 3 YL) 4 ( 3,5 DIMETHOXYPHENYL)MALEIMIDE; 4 AZAINDOLE; 5 AZAINDOLE; 6 AZAINDOLE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; ETHYL 2 ( 4 AZAINDOL 3YL) 2 OXOACETIC ACID; ETHYL 2 ( 5 AZAINDOL 3 YL) 2 OXOACETIC ACID; ETHYL 2 ( 6 AZAINDOL 3 YL) 2 OXOACETIC ACID; ETHYL 2 ( 7 AZAINDOL 3 YL) 2 OXOACETIC ACID; ETHYL 2 [ 1 (TERT BUTOXYCARBONYL) 5 AZAINDOL 3 YL] 2 OXOACETIC ACID; ETHYL 2 [ 1 (TERT BUTOXYCARBONYL) 6 AZAINDOL 3 YL] 2 OXOACETIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; IRINOTECAN; MALEIMIDE DERIVATIVE; PROTEIN KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; NONHUMAN;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; CHICK EMBRYO; FMS-LIKE TYROSINE KINASE 3; GLYCOGEN SYNTHASE KINASE 3; GROWTH INHIBITORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALEIMIDES; MOLECULAR STRUCTURE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84870021394     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301217c     Document Type: Article

References (40)

1. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 2007, 25 (15) 1960-1966
2. Ma, W. W.; Adjei, A. A. Novel agents on the horizon for cancer therapy CA - Cancer J. Clin. 2009, 59 (2) 111-137
3. Risau, W. Differentiation of endothelium FASEB J. 1995, 9 (10) 926-933
4. Conway, E. M.; Collen, D.; Carmeliet, P. Molecular mechanisms of blood vessel growth Cardiovasc. Res. 2001, 49 (3) 507-521
5. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis Nat. Med. 2000, 6 (4) 389-395
6. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease Nat. Med. 1995, 1 (1) 27-31
7. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases Nature 2000, 407 (6801) 249-257
8. Fan, T.-P. D.; Brem, S. Angiosuppression. In The Search for New Anti-Cancer Drugs; Kluwer Academic Publishers: Lancaster, U.K., 1992; Vol. 3, p 118-229.
9. Heidel, F.; Mack, T.; Razumovskaya, E.; Blum, M.-C.; Lipka, D.; Ballaschk, A.; Kramb, J.-P.; Plutizki, S.; Rönnstrand, L.; Dannhardt, G.; Fischer, T. 3,4-Diarylmaleimides - a novel class of kinase inhibitors - effectively induce apoptosis in FLT3-ITD-dependent cells Ann. Hematol. 2012, 91 (3) 331-344
10. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N. Engl. J. Med. 2004, 351 (4) 337-345
11. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 2004, 350 (23) 2335-2342
12. Markus Moehler, O. L.; Gockel, I.; Galle, P. R.; Lang, H. Multidisciplinary management of gastric and gastroesophageal cancers World J. Gastroenterol. 2008, 14 (24) 3773-3780
13. Moehler, M.; Mueller, A.; Trarbach, T.; Lordick, F.; Seufferlein, T.; Kubicka, S.; Geißler, M.; Schwarz, S.; Galle, P. R.; Kanzler, S.; Onkologie, G. A. I. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study Ann. Oncol. 2009, 22 (6) 1358-1366
14. Shepherd, F. A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E. H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabárbara, P.; Seymour, L. Erlotinib in previously treated non-small-cell lung cancer N. Engl. J. Med. 2005, 353 (2) 123-132
15. Peifer, C.; Krasowski, A.; Hämmerle, N.; Kohlbacher, O.; Dannhardt, G.; Totzke, F.; Schächtele, C.; Laufer, S. Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1 H -pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 Inhibitor J. Med. Chem. 2006, 49 (25) 7549-7553
16. Zhang, Z.; Yang, Z.; Wong, H.; Zhu, J.; Meanwell, N. A.; Kadow, J. F.; Wang, T. An effective procedure for the acylation of azaindoles at C-3 J. Org. Chem. 2002, 67 (17) 6226-6227
17. Mahadevan, I.; Rasmussen, M. Synthesis of pyrrolopyridines (azaindoles) J. Heterocycl. Chem. 1992, 29 (2) 359-367
18. Cash, M. T.; Schreiner, P. R.; Phillips, R. S. Excited state tautomerization of azaindole Org. Biomol. Chem. 2005, 3 (20) 3701-3706
19. Dormoy, J.-R.; Heymes, A. Synthese industrielle en serie ellipticine. I: Elaboration d'une nouvelle voie d'accès aux 6 H -pyrido[4,3: b ]carbazoles et analogues: A. Synthèse et étude des précurseurs Tetrahedron 1993, 49 (14) 2885-2914
20. Ottoni, O.; Neder, A. d. V. F.; Dias, A. K. B.; Cruz, R. P. A.; Aquino, L. B. Acylation of indole under Friedel-Crafts conditions an improved method to obtain 3-acylindoles regioselectively Org. Lett. 2001, 3 (7) 1005-1007
21. Faul, M. M.; Winneroski, L. L.; Krumrich, C. A. A new one step synthesis of maleimides by condensation of glyoxylate esters with acetamides Tetrahedron Lett. 1999, 40 (6) 1109-1112
22. Peifer, C.; Stoiber, T.; Unger, E.; Totzke, F.; Schächtele, C.; Marmé, D.; Brenk, R.; Klebe, G.; Schollmeyer, D.; Dannhardt, G. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors J. Med. Chem. 2006, 49 (4) 1271-1281
23. Dannhardt, G.; Peifer, C.; Plutizki, S.; Kramb, J., 3-(Indolyl)-4- Arymaleimide Derivatives and Their Use as Angiogenesis Inhibitors. EP Patent 1819697, 2007.
24. Dannhardt, G.; Fischer, T.; Heidel, F. H.; Kramb, J. P.; Plutizki, S. Use of 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide Derivatives in Leukemia Management. EP Patent 08858282.1, 2011.
25. Basel, Y.; Hassner, A. Di- tert -butyl dicarbonate and 4-(dimethylamino)pyridine revisited. Their reactions with amines and alcohols J. Org. Chem. 2000, 65 (20) 6368-6380
26. Lemmon, M. A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases Cell 2010, 141 (7) 1117-1134
27. Bennasroune, A.; Gardin, A.; Aunis, D.; Crémel, G.; Hubert, P. Tyrosine kinase receptors as attractive targets of cancer therapy Crit. Rev. Oncol./Hematol. 2004, 50 (1) 23-38
28. Zhang, H.-C.; Ye, H.; Conway, B. R.; Derian, C. K.; Addo, M. F.; Kuo, G.-H.; Hecker, L. R.; Croll, D. R.; Li, J.; Westover, L.; Xu, J. Z.; Look, R.; Demarest, K. T.; Andrade-Gordon, P.; Damiano, B. P.; Maryanoff, B. E. 3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3 Bioorg. Med. Chem. Lett. 2004, 14 (12) 3245-3250
29. Peifer, C.; Dannhardt, G. A novel quantitative chick embryo assay as an angiogenesis model using digital image analysis Anticancer Res. 2004, 24 (3A) 1545-1552
30. Aitkenhead, M.; Christ, B.; Eichmann, A.; Feucht, M.; Wilson, D. J.; Wilting, J. Paracrine and autocrine regulation of vascular endothelial growth factor during tissue differentiation in the quail Dev. Dyn. 1998, 212 (1) 1-13
31. Götschel, F.; Kern, C.; Lang, S.; Sparna, T.; Markmann, C.; Schwager, J.; McNelly, S.; von Weizsäcker, F.; Laufer, S.; Hecht, A.; Merfort, I. Inhibition of GSK3 differentially modulates NF-κB, CREB, AP-1 and β-catenin signaling in hepatocytes, but fails to promote TNF-α-induced apoptosis Exp. Cell Res. 2008, 314 (6) 1351-1366
32. Zhang, W.; Konopleva, M.; Shi, Y.-x.; McQueen, T.; Harris, D.; Ling, X.; Estrov, Z.; Quintás-Cardama, A.; Small, D.; Cortes, J.; Andreeff, M. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia J. Natl. Cancer Inst. 2008, 100 (3) 184-198
33. Davis, P. D.; Hill, C. H.; Lawton, G.; Nixon, J. S.; Wilkinson, S. E.; Hurst, S. A.; Keech, E.; Turner, S. E. Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides J. Med. Chem. 1992, 35 (1) 177-184
34. Matsuo, Y.; MacLeod, R.; Uphoff, C.; Drexler, H.; Nishizaki, C.; Katayama, Y.; Kimura, G.; Fujii, N.; Omoto, E.; Harada, M.; Orita, K. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23) Leukemia 1997, 11, 1469-1477
35. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 1983, 65 (1-2) 55-63
36. Nicoletti, I.; Migliorati, G.; Pagliacci, M. C.; Grignani, F.; Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry J. Immunol. Methods 1991, 139 (2) 271-279
37. Millipore. Lead Discovery - Kinases and Phosphatases. http://www.millipore.com/life-sciences/flx4/ld-kinases.
38. Sloan, M. J.; Phillips, R. S. Enzymatic synthesis of aza-l-tryptophans: the preparation of 5- and 6-aza-l-tryptophan Bioorg. Med. Chem. Lett. 1992, 2 (9) 1053-1056
39. Zhang, Z.; Yang, Z.; Meanwell, N. A.; Kadow, J. F.; Wang, T. A general method for the preparation of 4- and 6-azaindoles J. Org. Chem. 2002, 67 (7) 2345-2347
40. Dannhardt, G.; Kramb, J.; Plutizki, S. 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide Compounds and Their Use in Tumor Treatment. WO 2011/73092 A1, 2011.